Evome Medical Technologies Inc.
LNDZF · OTC
12/31/2023 | 2/28/2022 | 2/28/2021 | 2/29/2020 | |
|---|---|---|---|---|
| Revenue | $63 | $18 | -$0 | $0 |
| % Growth | 242% | 54,686.9% | -109.5% | – |
| Cost of Goods Sold | $40 | $12 | $12 | $0 |
| Gross Profit | $23 | $6 | -$12 | -$0 |
| % Margin | 36% | 32.6% | 36,914.6% | -5.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $24 | $6 | $1 | $2 |
| SG&A Expenses | $24 | $6 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $0 | -$2 | $0 |
| Operating Expenses | $28 | $6 | $1 | $2 |
| Operating Income | -$6 | -$5 | -$1 | -$2 |
| % Margin | -8.8% | -26.4% | 3,051.9% | -479.5% |
| Other Income/Exp. Net | -$10 | $0 | -$2 | $0 |
| Pre-Tax Income | -$16 | -$4 | -$3 | -$2 |
| Tax Expense | $0 | -$0 | $0 | $1 |
| Net Income | -$16 | -$4 | -$3 | -$2 |
| % Margin | -24.9% | -23.9% | 7,951.3% | -664.9% |
| EPS | -0.16 | -0.1 | -0.061 | -0.069 |
| % Growth | -60.3% | -63.7% | 11.8% | – |
| EPS Diluted | -0.16 | -0.1 | -0.061 | -0.069 |
| Weighted Avg Shares Out | 73 | 44 | 44 | 34 |
| Weighted Avg Shares Out Dil | 73 | 44 | 44 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $0 |
| EBITDA | -$10 | -$3 | -$1 | -$2 |
| % Margin | -16.6% | -17.7% | 4,285.3% | -464.1% |